Difference between revisions of "Venlafaxine-agomelatine"

From Psychiatrienet
Jump to: navigation, search
(Created page with '{{Drugswitch | from = venlafaxine | to = agomelatine | stop = | start = | info = * Venlafaxine stops the metabolism of agomelatine via CYP1A2 (90%) and via CYP2C9/2C19 (1...')
 
(10 intermediate revisions by 4 users not shown)
Line 3: Line 3:
 
| to = agomelatine  
 
| to = agomelatine  
 
| stop =  
 
| stop =  
 
+
{{stopVenlafaxine}}
 
| start =  
 
| start =  
 
+
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.
| info =
+
* '''Day 8:''' continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
* Venlafaxine stops the metabolism of agomelatine via CYP1A2 (90%) and via CYP2C9/2C19 (10%).}}
+
}}

Revision as of 11:42, 4 November 2015

Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from venlafaxine to agomelatine.[1] [2]

Nietinrijdenbord.png Stop venlafaxine
  • Before day 1: gradually reduce dosage of venlafaxine to a maximum of 75 mg/ day.
  • Day 1: reduce a dosage of 75 mg/day to 37,5 mg/day.
  • Day 8: stop administration of venlafaxine.
Eenrichtingbord.png Start agomelatine
  • Day 1: simultaneously start administration of agomelatine in a dosage of 25 mg/day.
  • Day 8: continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.[3]


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.